Clinical Trial Update: Efficacy and Tolerance of Baricitinib, a JAK Inhibitor, in the Treatment of Refractory Non-infectious Non-anterior Uveitis [Phase 3]

View source ↗

Summary

Phase 3 trial update evaluating efficacy and tolerability of baricitinib for refractory non-infectious non-anterior uveitis; currently not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-infectious Uveitis

Drugs mentioned

• Baricitinib (baricitinib)

Snippet

Sponsor: University Hospital, Rouen | Conditions: Active Non-anterior Non-infectious Uveitis | Phase 3 | Status: NOT_YET_RECRUITING